Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
WEBApr 12, 2024 · Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
WEBJun 13, 2024 · A study shows that lorlatinib (Lobrena) stops lung cancer growth and spread for 5 years or more in over half of people with ALK gene mutation. Learn how this drug outperforms crizotinib and how molecular testing can help guide treatment options.
After Four Decades, a Breakthrough for Lung Cancer
WEBLearn about just some of our achievements in this Annual Report. When Karen Milich stopped responding to lung cancer treatments, she enrolled in an MSK-led clinical trial testing a drug that targets the KRAS mutation. The drug, sotorasib, was a breakthrough, 40 years in the making.
Osimertinib Improves Survival in Lung Cancer - NCI
WEBJul 5, 2023 · A large study of people with early-stage lung cancer and EGFR mutations found that osimertinib, a targeted drug, increased their overall survival after surgery. However, some oncologists questioned the trial design and the benefits of …
Lung Cancer News -- ScienceDaily
WEBAug 26, 2024 · Information about lung cancer symptoms and treatments. Explore the latest medical research on cancers including experimental treatments.
Pfizer’s Lorbrena extends life for patients with rare lung cancer
WEBMay 31, 2024 · Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a...
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
WEBFeb 16, 2024 · Repotrectinib is a new drug that can shrink tumors in people with advanced lung cancer with ROS1 fusions, a genetic change that makes the cancer cells grow out of control. The drug was approved by FDA in 2023 and can overcome some resistance mutations that other ROS1-targeted drugs cannot.
Lung cancer - Latest research and news - Nature
WEB5 days ago · Latest Research and Reviews. Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
Adjuvant Immunotherapy Approved for Lung Cancer - NCI
WEBOct 26, 2021 · FDA has approved the immunotherapy atezolizumab (Tecentriq) as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer (NSCLC). With the approval, atezolizumab becomes the first checkpoint inhibitor approved as an adjuvant treatment for lung cancer.
US lung cancer survival rates rise, but it’s still the leading ... - CNN
WEBNov 14, 2023 · CNN — Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the...